Health Care [ 9/12 ] | Biotechnology [ 35/76 ]
NASDAQ | Common Stock
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States.
The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions.
The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity.
Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 24 | 0.00 Increased by +100.00% | -0.42 Increased by +100.00% |
| Mar 20, 24 | 0.00 Increased by +100.00% | -0.31 Increased by +100.00% |
| Nov 8, 23 | -0.36 Decreased by -9.09% | -0.37 Increased by +2.70% |
| Aug 11, 23 | -0.37 Decreased by -19.35% | -0.40 Increased by +7.50% |
| May 10, 23 | -0.33 Decreased by -13.79% | -0.41 Increased by +19.51% |
| Mar 22, 23 | -0.35 Decreased by -29.63% | -0.35 |
| Nov 10, 22 | -0.33 Decreased by -175.00% | -0.47 Increased by +29.79% |
| Aug 10, 22 | -0.31 Decreased by -158.33% | -0.58 Increased by +46.55% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -9.20 M Increased by +43.26% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -9.30 M Increased by +41.73% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -8.37 M Increased by +39.46% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Increased by +100.00% | -17.34 M Decreased by -31.16% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -16.21 M Decreased by -415.85% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by -100.00% | -15.97 M Decreased by -191.08% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by -100.00% | -13.83 M Decreased by -147.02% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | -2.72 M Decreased by -1.39 K% | -13.22 M Increased by +20.83% | Increased by +486.68% Increased by +106.12% |